These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-004295-37 A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer. 2010-12-21 due-trials
Reported results 2005-000331-14 A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX -6) every 2 weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment ... 2012-12-31 due-trials
Listed as ongoing, but also has a completion date 2005-000395-41 Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy with Velcade (Bortezomib), Adriamycin, and Dexamethasone (PAD) as Therapy for Patients with relapsed or refracto... 2016-05-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004420-39 An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADE (Bortezomib) in Patients with Malignant Pleural Mesothelioma 2009-12-04 bad-data
Reported results 2005-004822-19 A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide ... 2016-06-30 due-trials
Ongoing 2006-001657-94 A randomised adjuvant Phase III Trial of six cycles of docetaxel and hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiot... not-yet-due
Reported results 2006-003332-29 A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial 2009-06-26 due-trials
Completed, but no date Terminated 2007-001195-36 A Randomised Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determ... bad-data
Ongoing 2007-003195-19 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non- Small Cell Lung Cancer (NSCLC) not-yet-due
Other 2007-003810-32 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. not-yet-due
Ongoing 2007-004266-40 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen F... not-yet-due
Not reported 2008-001250-40 An open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide, And Rituximab in Patients with Chronic Lymphocytic Leukaemia who are Newly Diagnosed, have ... 2019-11-21 due-trials
Not reported 2008-004551-30 A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr... 2016-02-15 due-trials
Reported results 2008-005062-31 Phase II single agent sorafenib in the treatment of relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients 2013-05-08 due-trials
Reported results 2008-006907-22 A Phase II study of lapatanib and capecitabine in the treatment of metastatic pancreatic cancer 2010-08-11 due-trials
Not reported 2010-020966-34 A phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Traztuzumab and Lapatinib) in Erb B2 positive breast cancer patients 2018-05-22 due-trials
Not reported 2010-021587-15 A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer 2018-02-28 due-trials
Reported results 2010-022770-13 A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy 2020-07-15 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-001858-28 Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator’s ... 2022-08-04 bad-data
Completed, but no date 2011-003847-22 ECOG 2809: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy bad-data
Trial is partly outside EEC 2011-004257-29 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma bad-data
Ongoing 2011-004943-32 ICORG 11-24-NSABP PROTOCOL B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclopho... not-yet-due
Reported results Terminated 2011-005002-30 Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer. 2012-12-14 due-trials
Listed as ongoing, but also has a completion date 2011-005189-39 A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2 positive metastatic breast cancer. ICORG 11-10/TH ... 2023-02-17 bad-data
Ongoing 2012-000576-42 S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer wit... not-yet-due
Reported results 2012-000709-59 A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy... 2018-12-05 due-trials
Completed, but no date 2012-000750-66 Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma bad-data
Reported results 2012-001248-23 Treatment of Inoperable Colorectal Cancer with Electrochemotherapy through an Endoscopic System 2017-07-27 due-trials
Not reported Terminated 2013-002625-35 Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC) 2015-05-21 due-trials
Reported results 2013-004850-97 A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer 2021-11-23 due-trials
Ongoing 2013-005008-32 A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma not-yet-due
Reported results 2014-001128-31 Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostate c... 2021-01-19 due-trials
Other 2014-003190-42 Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. not-yet-due
Ongoing 2014-003191-23 Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer. not-yet-due
Not reported 2015-002066-24 A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma 2018-02-27 due-trials
Exempt 2015-003687-36 Phase IB/II clinical trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer 2022-05-06 not-yet-due
Ongoing 2016-002244-16 A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer not-yet-due
Ongoing 2016-005197-35 A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma. not-yet-due
Ongoing 2019-004818-34 DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide t... not-yet-due
Reported results 2020-000073-24 Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer. 2022-09-30 due-trials
Ongoing 2020-000946-32 Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients w... not-yet-due
Ongoing 2021-006276-16 PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine. not-yet-due
Ongoing 2022-002485-32 Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach to... not-yet-due
Ongoing 2022-002877-27 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peri... not-yet-due